A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2017
At a glance
- Drugs Vesatolimod (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 14 Aug 2017 Planned End Date changed from 18 Oct 2019 to 1 Oct 2019.
- 26 Jan 2017 Planned End Date changed from 1 Oct 2019 to 18 Oct 2019.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.